LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Settembre 2024 - 10:01PM
Business Wire
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today
announced that a majority of the independent members of LENSAR’s
board of directors granted three newly-hired non-executive
employees stock options to purchase an aggregate of 2,425 shares of
the Company’s common stock. The options were granted as of
September 3, 2024, as inducements material to each employee
entering into employment with the Company. The options were granted
in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $4.63 per share, which is
equal to the closing price of the Company’s common stock on the
grant date. The options vest as to 25% of the total amount of the
award on the one-year anniversary of the grant date and in
thirty-six substantially equal monthly installments thereafter,
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term. The options are subject to
the terms and conditions of LENSAR’s 2024 Employment Inducement
Incentive Award Plan and a stock option agreement covering the
grant.
About LENSAR
LENSAR is a commercial-stage medical device company focused on
designing, developing, and marketing advanced systems for the
treatment of cataracts and the management of astigmatism as an
integral aspect of the cataract procedure. LENSAR has developed its
ALLY® Adaptive Cataract Treatment System as a compact, highly
ergonomic system utilizing an extremely fast dual-pulse laser and
integrating AI into proprietary imaging and software. ALLY is
designed to transform premium cataract surgery by utilizing
LENSAR’s advanced technologies with the ability to perform the
entire procedure in a sterile operating room or in-office surgical
suite, delivering operational efficiencies and reducing overhead.
ALLY includes LENSAR’s proprietary Streamline® software technology,
which is designed to guide surgeons to achieve better outcomes.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240904852366/en/
Thomas R. Staab, II, CFO ir.contact@lensar.com
Lee Roth / Cameron Radinovic Burns McClellan for LENSAR
lroth@burnsmc.com / cradinovic@burnsmc.com
Grafico Azioni LENSAR (NASDAQ:LNSR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni LENSAR (NASDAQ:LNSR)
Storico
Da Gen 2024 a Gen 2025